dc.contributor.author | Cavalcante, MB | |
dc.contributor.author | Sarno, M | |
dc.contributor.author | Araujo Júnior, E | |
dc.contributor.author | Da Silva Costa, F | |
dc.contributor.author | Barini, R | |
dc.date.accessioned | 2021-10-13T02:44:07Z | |
dc.date.available | 2021-10-13T02:44:07Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 0932-0067 | |
dc.identifier.doi | 10.1007/s00404-020-05830-w | |
dc.identifier.uri | http://hdl.handle.net/10072/408976 | |
dc.description.abstract | Dear Editor,
It was with great interest that we read and analyzed the letter to the editor of Xiang et al. The authors presented initial outcomes on the safety of lymphocyte immunotherapy (LIT) in a group of patients diagnosed with alloimmune recurrent miscarriage (RM) during November 1, 2019–January 17, 2020 in Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology. | |
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartofpagefrom | 571 | |
dc.relation.ispartofpageto | 572 | |
dc.relation.ispartofissue | 2 | |
dc.relation.ispartofjournal | Archives of Gynecology and Obstetrics | |
dc.relation.ispartofvolume | 304 | |
dc.subject.fieldofresearch | Immunology | |
dc.subject.fieldofresearchcode | 3204 | |
dc.title | Reply to letter to the editor: “Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China” (Letter) | |
dc.type | Journal article | |
dc.type.description | C2 - Articles (Other) | |
dcterms.bibliographicCitation | Cavalcante, MB; Sarno, M; Araujo Júnior, E; Da Silva Costa, F; Barini, R, Reply to letter to the editor: “Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China”, Archives of Gynecology and Obstetrics (Letter), 2021, 304 (2), pp. 571-572 | |
dcterms.dateAccepted | 2020-09-28 | |
dc.date.updated | 2021-10-08T04:44:11Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Da Silva Costa, Fabricio | |